Valneva SE
Chairman of the supervisory board) | |
Products | Development of vaccines |
---|---|
Website | www |
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.[1][2][3]
Background
Valneva was founded in 2013 through the merger of Austrian company Intercell and French company Vivalis SA.[4][5] It has been listed since 28 May 2013 on the Euronext Paris in Paris and used to be listed on the Vienna Stock Exchange.[citation needed]
Products
Released vaccines
Vaccines marketed by Valneva include
Failed developments
Some of its candidates have failed in clinical trials: VLA43, a
COVID-19 vaccine
Valneva along with Dynavax Technologies
Valneva and dynavax technologies
The company manufacturing facility in Livingston, Scotland produces the VLA2001 vaccine.[18][19]
In September 2021, Valneva announced that the UK government had cancelled their vaccine order.[20] The cancellation reason was not officially given, but seemed to be related to difficulties getting building materials due to Brexit[21] and not vaccine quality.
On 14 April 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do so.[22]
On 17 May 2022 the European Commission cancelled its advance purchase agreement for the vaccine which would have seen Valneva provide 60 million doses over two years.[23]
Other vaccines under development
Valneva is also working on four other vaccines:[citation needed]
- Ixchiq, a chikungunya vaccine approved by the Food and Drug Administration in November 2023.[24] The application for its vaccine was accepted by the European Medicines Agency on November 27, 2023.[25]
- VLA15, a vaccine against Lyme disease that is planned for release around 2024.
- A vaccine against Clostridiodes difficile infection
- A vaccine against the Zika virus
On 20 June 2022, American biotech firm Pfizer announced a 90.5 million euro ($95.24 million) investment, buying an 8.1% stake in Valneva as part of a partnership to tackle Lyme disease.[26]
References
- ^ "Manufacturing and Services". Valneva. Retrieved 11 January 2021.
- ^ "Marketing and Distribution". Valneva. Retrieved 11 January 2021.
- ^ "Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Valneva. 9 January 2020. Retrieved 11 January 2021.
- ^ "Vivalis to Buy Intercell AG in European Biotech Merger for $174 Million". BioSpace. 17 December 2012. Retrieved 2 February 2021.
- ^ "Vivalis announces that the Intercell AG Extraordinary General Meeting has approved the proposed merger of equals with Vivalis SA to create Valneva SE". GlobeNewswire. 28 February 2013. Retrieved 2 February 2021.
- ^ "Ixiaro, Japanese-encephalitis vaccine (inactivated, adsorbed)". European Medicines Agency. 5 June 2009. Retrieved 25 April 2017.
- ^ "Dukoral, cholera vaccine (inactivated, oral)". European Medicines Agency. 30 April 2009. Retrieved 25 April 2017.
- ^ "Valneva writes off hospital-acquired infection vaccine following PhII/III miss". FierceBiotech, Questex LLC. 2016-09-01. Retrieved 2017-04-25.
- ^ "Merck ends trial of Intercell's MRSA vaccine". Reuters. 2011-06-08. Retrieved 2017-04-25.
- ^ "Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 22 August 2007. Retrieved 15 August 2008.
- ^ "Valneva, Dynavax Inks $1.5 Billion COVID-19 Vaccine Supply Deal with UK".
- ^ a b "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.
- ^ a b "Covid: Clinical trials begin for Valneva vaccine". BBC News. 16 December 2020. Retrieved 11 January 2021.
- ^ "Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate". Valneva SE. 16 December 2020. Retrieved 18 December 2020.
- ^ a b "Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults". clinicaltrials.gov. U.S. National Library of Medicine. 30 December 2020. Retrieved 11 January 2021.
- ^ "Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine – Valneva".
- ^ Nawrat, Allie (6 August 2020). "Q&A with Valneva: UK Government scales up Covid-19 manufacturing". Pharmaceutical Technology. Retrieved 11 January 2021.
- ^ "Biotech Valneva: European Union to buy '30 million doses of unique West Lothian Covid-19 vaccine'". Edinburgh News. 14 January 2021. Retrieved 18 January 2021.
- ^ Yeomans, Emma. "Scotland factory to produce Valneva Covid vaccine". The Times. Retrieved 18 January 2021.(Subscription required.)
- ^ "UK scraps Covid-19 vaccine deal with French firm Valneva". BBC News. 13 September 2021.
- ^ "U.K. Threw Covid Vaccine Maker Under Bus over Contract, Valneva CEO Says". Bloomberg.com. 24 November 2021.
- ^ "Regulatory approval of COVID-19 Vaccine Valneva". GOV.UK. Retrieved 2022-04-14.
- ^ Dunleavy, Kevin (2022-05-17). "Valneva's COVID-19 vaccine faces uncertain future after Europe cancels supply contract". Fierce Pharma. Retrieved 2022-06-21.
- ^ Malhi, Sabrina (10 November 2023). "FDA approves first vaccine against mosquito-borne virus chikungunya". The Washington Post. Retrieved 13 November 2023.
- ^ Sorgho, Olivier (27 November 2023). "Valneva says EU regulator accepts its chikungunya vaccine application". Reuters. Retrieved 27 November 2023.
- ^ "Pfizer to buy 8.1% stake in French vaccines company Valneva". The Economic Times. Retrieved 2022-06-21.